Despite major advances in antiretroviral therapy (ART), HIV remains incurable due to the persistence of latent viral reservoirs and immune evasion through immune checkpoint dysregulation. FireGate Bioscience LLC presents a novel Triplet Immunologic Modulation framework designed to achieve durable ART-free remission by simultaneously targeting three synergistic immunologic axes: CCR5 blockade, PD-L1 modulation, and broadly neutralizing antibody (bNAb)–mediated clearance. This triplet approach integrates receptor-level viral entry inhibition, restoration of exhausted T-cell function, and antibody-driven clearance of infected cells, forming a unified strategy that seeks to both suppress and reprogram HIV’s pathogenic reservoirs. Building on clinical precedents such as the Berlin and London patient cases, the FireGate framework applies non-gene-editing, pharmacologic, and immunotherapeutic principles to re-establish immune homeostasis and functional control. The concept outlines a scalable translational pathway leveraging in vitro, in silico, and ex vivo validation to model triplet synergy and durability. This platform aims to bridge immunology, virology, and oncology insights, positioning FireGate Bioscience’s pipeline as a next-generation therapeutic model for chronic viral infections and immune restoration.

Preclinical evaluation of the triplet framework will utilize a phased approach combining in vitro, in silico, and ex vivo analyses: In vitro assays to measure CCR5 blockade efficacy and PD-L1 expression modulation across immune cell subsets. Computational modeling (in silico) to predict triplet pharmacodynamics, receptor cross-talk, and immune tolerance thresholds. Ex vivo evaluation using PBMCs from HIV-positive donors to confirm immune reactivation, viral suppression, and checkpoint recovery. Data integration and pathway analysis performed through FireGate’s Lux Veritas™ AI engine to identify optimal synergy ratios and translational dosing models. This structured preclinical model allows empirical validation of FireGate’s triplet hypothesis and supports readiness for IND-enabling studies and regulatory engagement